tirzepatide no longer shortage FDA says of GLP-1 is over FDA says the tirzepatide weight-loss

According to NFPs (an Aon company) 2026 U.S

GLP-1 medications reduce appetite and increase feelings of fullness by slowing stomach emptying and acting on appetite-regulating centers in the brain, Zimmermann says

The GLP-1 agonists semaglutide and liraglutide, which seem new and therefore more risky, have been used for almost 20 years for people with type 2 diabetes and have been shown to be safe and well-tolerated, Levy says

Klenner T, Berger MR, Zelezny O, Fink M, Schmhl D

The regulatory approval arrived on the back of a clinical trial which found that participants lost an average of 14 per cent of their body weight over 64 weeks

Im going to do a youtube video with progress pics